NO20090667L - Tartratsalt av (7S)-7-[(5-fluor-2-metyl-benzyl)oksy]-2-[(2R)-2-metylpiperazin-1-yl]-6,7-dihydro-5H-syklopenta[b] pyridin - Google Patents

Tartratsalt av (7S)-7-[(5-fluor-2-metyl-benzyl)oksy]-2-[(2R)-2-metylpiperazin-1-yl]-6,7-dihydro-5H-syklopenta[b] pyridin

Info

Publication number
NO20090667L
NO20090667L NO20090667A NO20090667A NO20090667L NO 20090667 L NO20090667 L NO 20090667L NO 20090667 A NO20090667 A NO 20090667A NO 20090667 A NO20090667 A NO 20090667A NO 20090667 L NO20090667 L NO 20090667L
Authority
NO
Norway
Prior art keywords
tartrate salt
cyclopenta
dihydro
oxy
fluoro
Prior art date
Application number
NO20090667A
Other languages
English (en)
Norwegian (no)
Inventor
Kevin Kun-Chin Liu
Yuan Zeng
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20090667L publication Critical patent/NO20090667L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20090667A 2006-07-14 2009-02-11 Tartratsalt av (7S)-7-[(5-fluor-2-metyl-benzyl)oksy]-2-[(2R)-2-metylpiperazin-1-yl]-6,7-dihydro-5H-syklopenta[b] pyridin NO20090667L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83089006P 2006-07-14 2006-07-14
PCT/IB2007/002025 WO2008010073A1 (en) 2006-07-14 2007-07-09 Tartrate salt of (7s)-7-[(5-fluoro-2-methyl-benzyl)oxy]-2-[(2r)-2-methylpiperazin-1-yl]-6,7-dihydro-5h-cyclopenta[b]pyridine

Publications (1)

Publication Number Publication Date
NO20090667L true NO20090667L (no) 2009-02-11

Family

ID=38542082

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20090667A NO20090667L (no) 2006-07-14 2009-02-11 Tartratsalt av (7S)-7-[(5-fluor-2-metyl-benzyl)oksy]-2-[(2R)-2-metylpiperazin-1-yl]-6,7-dihydro-5H-syklopenta[b] pyridin

Country Status (16)

Country Link
US (1) US20100004259A1 (enExample)
EP (1) EP2044029B1 (enExample)
JP (1) JP4312243B2 (enExample)
KR (1) KR20090029299A (enExample)
CN (1) CN101506172A (enExample)
AR (1) AR062068A1 (enExample)
AT (1) ATE496894T1 (enExample)
AU (1) AU2007274710A1 (enExample)
CA (1) CA2657640A1 (enExample)
DE (1) DE602007012254D1 (enExample)
IL (1) IL196417A0 (enExample)
MX (1) MX2009000508A (enExample)
NO (1) NO20090667L (enExample)
TW (1) TW200821293A (enExample)
WO (1) WO2008010073A1 (enExample)
ZA (1) ZA200901051B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5520051B2 (ja) 2007-11-15 2014-06-11 武田薬品工業株式会社 縮合ピリジン誘導体およびその用途
JP5124308B2 (ja) 2008-02-26 2013-01-23 株式会社リコー トナー、該トナーを用いた現像剤、トナー入り容器、プロセスカートリッジ、及び画像形成方法
WO2010079605A1 (ja) * 2009-01-09 2010-07-15 東レ・ファインケミカル株式会社 高純度１－ベンジル－３－アミノピロリジンの製造方法
JO3250B1 (ar) 2009-09-22 2018-09-16 Novartis Ag إستعمال منشطات مستقبل نيكوتينيك أسيتيل كولين ألفا 7
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
JP6472757B2 (ja) 2013-01-16 2019-02-20 ストライカー・コーポレイション 見通し線エラーを示し、かつ低減させるためのナビゲーションシステムおよび方法
US9993273B2 (en) 2013-01-16 2018-06-12 Mako Surgical Corp. Bone plate and tracking device using a bone plate for attaching to a patient's anatomy
US10095785B2 (en) * 2013-09-30 2018-10-09 Sonos, Inc. Audio content search in a media playback system
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
US10606822B2 (en) * 2014-11-01 2020-03-31 Hewlett Packard Enterprise Development Lp Dynamically updating metadata
US10537395B2 (en) 2016-05-26 2020-01-21 MAKO Surgical Group Navigation tracker with kinematic connector assembly
ES3001152T3 (es) 2016-12-20 2025-03-04 Lts Lohmann Therapie Systeme Ag Sistema terapéutico transdérmico que contiene asenapina y polisiloxano o poliisobutileno
PL3338768T3 (pl) 2016-12-20 2020-05-18 Lts Lohmann Therapie-Systeme Ag Transdermalny system terapeutyczny zawierający asenapinę
US11033512B2 (en) 2017-06-26 2021-06-15 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and silicone acrylic hybrid polymer
PL3652176T3 (pl) * 2017-07-11 2022-04-04 Boehringer Ingelheim International Gmbh Podstawione pochodne ksantyny
KR102802121B1 (ko) 2018-06-20 2025-05-02 에르테에스 로만 테라피-시스테메 아게 아세나핀을 함유하는 경피 치료 시스템
CN118806732A (zh) 2018-06-20 2024-10-22 罗曼治疗系统股份公司 含有阿塞那平的透皮治疗系统
WO2020087031A1 (en) 2018-10-26 2020-04-30 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
EP3669876A1 (en) * 2018-12-18 2020-06-24 Aelis Farma 3béta-(benzyloxy)-17alpha-methyl-pregn-5-en-20-one for use in the treatment of cognitive disorders
WO2023248222A1 (en) * 2022-06-21 2023-12-28 Technion Research & Development Foundation Limited 5-ht2c receptor modulating agents for the treatment of neurodegenerative, mental, cognitive and autoimmune cns disorders

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4985352A (en) * 1988-02-29 1991-01-15 The Trustees Of Columbia University In The City Of New York DNA encoding serotonin 1C (5HT1c) receptor, isolated 5HT1c receptor, mammalian cells expressing same and uses thereof
US5019574A (en) * 1988-09-30 1991-05-28 Chugai Seiyaku Kabushiki Kaisha 3,4-diaminoquinoline and 3,4-diamino-5,6,7,8-tetrahydroquinoline compounds useful for improving psychoneural function
DE4326151A1 (de) * 1993-08-04 1995-02-09 Hoechst Ag Aromatische Verbindungen und ihre Verwendung in flüssigkristallinen Mischungen
TW334423B (en) * 1993-10-22 1998-06-21 Hoffmann La Roche Tricyclic 1-aminoethylpyrrole-derivatives
TW270114B (enExample) * 1993-10-22 1996-02-11 Hoffmann La Roche
US5698766A (en) * 1995-04-05 1997-12-16 The Regents Of The University Of California Transgenic animal model for testing drugs for treating eating disorders and epilepsy
US6875769B2 (en) * 1996-05-23 2005-04-05 Pfizer Inc. Substituted6,6-hetero-bicyclicderivatives
US6040448A (en) * 1997-10-24 2000-03-21 Neurogen Corporation Certain 1-(2-naphthyl) and 1-(2-azanaphthyl)-4-(1-phenylmethyl) piperazines, dopamine receptor subtype specific ligands
KR100523184B1 (ko) * 1998-02-26 2005-10-24 악조 노벨 엔.브이. 아제티딘 및 피롤리딘의 유도체
WO2000012077A1 (en) * 1998-09-01 2000-03-09 Bristol-Myers Squibb Company Potassium channel inhibitors and method
GB9819019D0 (en) * 1998-09-01 1998-10-28 Cerebrus Ltd Chemical compounds II
GB9819035D0 (en) * 1998-09-01 1998-10-28 Cerebrus Res Ltd Chemical compounds VII
GB9819033D0 (en) * 1998-09-01 1998-10-28 Cerebrus Ltd Chemical compounds VI
US6465467B1 (en) * 1999-05-21 2002-10-15 Biovitrum Ab Certain aryl-aliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases
EP1250230B1 (de) * 2000-01-25 2005-04-27 Koenig & Bauer Aktiengesellschaft Bogendruckmaschine mit siebdruckzylindern
EP1152407A3 (en) * 2000-04-25 2006-10-25 Matsushita Electric Industrial Co., Ltd. Optical disk, method for producing the same, and apparatus for producing the same
SE0004245D0 (sv) * 2000-11-20 2000-11-20 Pharmacia Ab Novel compounds and their use
ES2278016T3 (es) * 2001-04-09 2007-08-01 Novartis Vaccines And Diagnostics, Inc. Compuestos guanidino como agonistas del receptor de melanocortina 4 (mc4-r).
US6825198B2 (en) * 2001-06-21 2004-11-30 Pfizer Inc 5-HT receptor ligands and uses thereof
US6953787B2 (en) * 2002-04-12 2005-10-11 Arena Pharmaceuticals, Inc. 5HT2C receptor modulators
WO2004007471A1 (ja) * 2002-07-12 2004-01-22 Yamanouchi Pharmaceutical Co., Ltd. Ｎ−フェニル−（２ｒ，５ｓ）ジメチルピペラジン誘導体
WO2004091485A2 (en) * 2003-04-11 2004-10-28 Taigen Biotechnology Aminoquinoline compounds
US7101881B2 (en) * 2003-06-11 2006-09-05 Pfizer Inc Tetrahydroquinolines
US20070015771A1 (en) * 2004-07-29 2007-01-18 Threshold Pharmaceuticals, Inc. Lonidamine analogs
AP2007004144A0 (en) * 2005-03-31 2007-08-31 Pfizer Prod Inc Cyclopentapyridine and tetrahydroquinoline derivatives

Also Published As

Publication number Publication date
KR20090029299A (ko) 2009-03-20
AU2007274710A1 (en) 2008-01-24
CA2657640A1 (en) 2008-01-24
ATE496894T1 (de) 2011-02-15
IL196417A0 (en) 2009-09-22
TW200821293A (en) 2008-05-16
EP2044029A1 (en) 2009-04-08
WO2008010073A1 (en) 2008-01-24
EP2044029B1 (en) 2011-01-26
JP2008044931A (ja) 2008-02-28
MX2009000508A (es) 2009-01-27
WO2008010073A8 (en) 2009-03-05
JP4312243B2 (ja) 2009-08-12
DE602007012254D1 (de) 2011-03-10
US20100004259A1 (en) 2010-01-07
AR062068A1 (es) 2008-10-15
ZA200901051B (en) 2010-01-27
CN101506172A (zh) 2009-08-12

Similar Documents

Publication Publication Date Title
NO20090667L (no) Tartratsalt av (7S)-7-[(5-fluor-2-metyl-benzyl)oksy]-2-[(2R)-2-metylpiperazin-1-yl]-6,7-dihydro-5H-syklopenta[b] pyridin
MX2010008638A (es) Furo-[3,2-c]piridinas y tieno[3,2-c]piridinas.
EA200700617A1 (ru) Новые пиридиновые производные и их применение в качестве позитивных аллостерических модуляторов mglur2-рецепторов
WO2007038209A3 (en) Fused tetracyclic mglur1 antagonists as therapeutic agents
MA31442B1 (fr) 3-(imidazolyl)-pyrazolo [3,4-b]pyridines
SG195085A1 (en) Pyrazolo[3,4-d]pyrimidine compounds and their use as pde2 inhibitors and/or cyp3a4 inhibitors
TN2011000339A1 (en) Poly (adp-ribose) polymerase (parp) inhibitors
UA102251C2 (ru) Производные аминодигидротиазина как ингибиторы васе для лечения болезни альцгеймера
JO3107B1 (ar) عملية لتحضير ميثيل {6،4- داي أمينو-2-[1-(2- فلوروبنزيل)-1H- بيرازولو[4،3b-] بيريدين-3- يل] بيريميدين-5- يل} ميثيل كربامات وتنقيته للاستخدام كمركب نشط دوائيا
EA201000332A1 (ru) 1,3-двузамещенные 4-фенил-1н-пиридин-2-оны
NZ598269A (en) Aryl sulphone derivatives as calcium channel blockers
EA201000331A1 (ru) 1',3-двузамещенные 4-(арил-х-фенил)-1h-пиридин-2-оны
TN2011000379A1 (en) [1, 2, 4] triazolo [1,5-a ] pyridines as kinase inhibitors
MY147320A (en) Process for the preparation of piperazinyl and diazepanyl benzamide derivatives
NO20080393L (no) Halogenerte pyrazolo [1,5-A] pyrimidiner, fremgangsmater, anvendelse som GABA-A reseptorligander, sammensetninger og intermediater
MA35407B1 (fr) Modulateurs allostériques positifs des récepteurs nicotiniques d'acétylcholine
WO2009120192A3 (en) Processes for the preparation of benzo-fused dioxin derivatives
NO20072972L (no) Terapeutiske pyrazolo[3,4-B]pyridiner og indazoler
IL187001A0 (en) Preparation of (s)-4-fluromethyl-dihydro-furan -2-one
WO2008011484A3 (en) Nicotinic desensitizers and methods of selecting, testing, and using them
WO2007127421A3 (en) Process for the synthesis of (+) and (-)-1-aryl-3-azabicyclo[3.1.0]hexanes
NZ601021A (en) Aminoalkylpyrimidine derivatives as histamine h4 receptor antagonists
TW200833665A (en) 1H-quinolin-4-one compounds, processes, uses and compositions
MX2012003603A (es) Derivados de 3,5-diciano-4-(1h-indazol-5-il)-2,6-dimetil-1,4-dihid ropiridina fluoro-sustituidos y procedimientos de uso de los mismos.
MX2008002366A (es) Antagonistas triciclicos fusionados de mglur1 como agentes terapeuticos.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application